STOCK MARKET BSE NSE

Remdesivir not for home use, meant for serious patients, says Government amid rise in demand

Remdesivir is listed for use in serious COVID-19 patients in the Clinical Management Protocols for COVID-19 as an investigational therapy.

Published: 13th April 2021 08:06 PM  |   Last Updated: 13th April 2021 08:06 PM   |  A+A-

Early studies testing remdesivir in patients hospitalized with COVID-19 found that those who received the treatment recovered quicker than those who didn't.

For representational purposes

By PTI

NEW DELHI: The Centre on Tuesday said doctors should ensure "rational and judicious" use of anti-viral drug Remdesivir, underlining it is to be given only to serious COVID-19 patients in hospitals and is not to be used in home settings.

At a weekly press conference, NITI Aayog member (Health) Dr V K Paul said, "Remdesivir is to be used only in those who require hospitalisation and are on oxygen support. That is the precondition. There is no question of its use in the home setting and for mild cases, and it is not to be procured from chemist shops." 

Remdesivir is listed for use in serious COVID-19 patients in the Clinical Management Protocols for COVID-19 as an investigational therapy.

As the shortage of Remdesivir was reported in some areas, its export was banned and the medicine is available in plenty, Paul said, adding that "queuing outside chemist shops to procure Remdesivir is creating distortions".

"We appeal to physicians to ensure rational, correct and judicious use of Remdesivir in hospitalised patients," he said.

In view of a sudden spike in demand due to the surge in COVID-19 cases, India on Sunday banned the export of injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the situation improves.

To ensure easy access of hospitals and patients to Remdesivir, all domestic manufactures of Remdesivir have also been advised to display on their website, details of their stockists/distributors to facilitate access to the drug, the Union Health Ministry had said.

 Drug inspectors and other officers have been directed to verify stocks and check their malpractices and also take other effective actions to curb hoarding and black marketing.

The State Health Secretaries will review this with the drug inspectors of the respective states and UTs, the ministry had said on Sunday.

The Centre has also advised the states that the extant  'National Clinical Management Protocol for COVID-19', which is based on evidence, has been developed after many interactions by a committee of experts and is the guiding document for the treatment of COVID-19 patients.

In the Protocol, Remdesivir is listed as an investigational therapy, i.e. where informed and shared decision-making is essential, besides taking note of contraindications mentioned in the detailed guidelines, the ministry said.

The states and UTs have been advised that these steps should again be communicated to all hospitals, both in the public and private sector, and compliance monitored.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp